Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. März 2016 09:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 28th Annual ROTH Conference

NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 28th Annual ROTH Conference...
14. März 2016 07:31 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Fourth Quarter 2015 Financial Results

NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended December 31, 2015. Ivan Bergstein, M.D., Stemline’s...
03. März 2016 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference

NEW YORK, March 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the Cowen and Company 36th Annual...
04. Februar 2016 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

NEW YORK, Feb. 4, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 18th Annual BIO CEO & Investor...
05. Januar 2016 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 34th Annual J.P. Morgan...
22. Dezember 2015 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Opening of SL-801 IND

NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the opening of its SL-801 Investigational New Drug (IND) application and initiation of a broad...
07. Dezember 2015 11:23 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Presents Clinical Update From Ongoing SL-401 Pivotal BPDCN Trial at the American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the presentation of positive clinical data, including high response rates, from the lead-in and...
04. Dezember 2015 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Five Presentations, Including SL-401 Clinical Update From Ongoing Pivotal BPDCN Trial, at the Upcoming American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 4, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401 and SL-801 will be the subject of five poster presentations at the 2015 American...
03. Dezember 2015 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference

NEW YORK, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Oppenheimer 26th Annual Healthcare...
06. November 2015 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2015 Financial Results

NEW YORK, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended September 30, 2015. Ivan Bergstein, M.D., Stemline's Chief...

Vorherige Seite